• Dr. Piotr Witkowski MD PhD, Professor of Surgery and Director of the Pancreatic and Islet Transplant Program, and his islet transplant team at University of Chicago Medicine authored an abstract that will be presented, including new data from the ongoing Phase I/II clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D). 

LONDON, Ontario; BOSTON, Massachusetts – August 15, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases such as Type 1 Diabetes, today announced a short oral presentation at the upcoming European Association for the Study of Diabetes (EASD) taking place September 9-13, 2024 in Madrid, Spain.

Additional details, including accepted abstracts, are available on the EASD website at www.easd.org   In alignment with the embargo policy, Sernova plans to share details from Dr. Witkowski’s talk, following the presentation.

Presentation details:

European Association for the Study of Diabetes - 2024 Annual Meeting – Madrid, Spain

Oral Event F: Improving Islet Transplantation - Thursday September 12, 2024

2:00pm to 3:00pm Central European Time

Abstract # 447: Islet allotransplantation into pre-vascularized Sernova Cell Pouch™: Interim Results: P. Witkowski, N. Wojcik, S. Gondek, J. Tomecki, K. Milejczyk, B. Juengel, L. Wang, J. J. Fung, R. Barth, USA.

Sernova Corp continues to collaborate closely with leading academic, pharmaceutical and clinical institutions to expand the scope and impact of its technology. The company anticipates further advancements as it progresses through additional cohorts and trials, with the ultimate goal of offering a scalable solution for insulin-dependent diabetes plus other chronic diseases.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes

VP, Investor Relations

Sernova Corp.

Tel: +1 519-902-7923

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Website: www.sernova.com

FORWARD-LOOKING INFORMATION  

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.